Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jul 30;21(3):309-19.
doi: 10.5056/jnm15105.

Unmet Needs in the Treatment of Gastroesophageal Reflux Disease

Ram Dickman  1 , Carla Maradey-Romero  1 , Rachel Gingold-Belfer  1 , Ronnie Fass  1
Affiliations

Unmet Needs in the Treatment of Gastroesophageal Reflux Disease

Ram Dickman et al. J Neurogastroenterol Motil. .

Erratum in

  • Corrigendum.
    Dickman R, Maradey-Romero C, Gingold-Belfer R, Fass R. Dickman R, et al. J Neurogastroenterol Motil. 2019 Jan 31;25(1):173. doi: 10.5056/jnm25011. J Neurogastroenterol Motil. 2019. PMID: 30646489 Free PMC article.

Abstract

Gastroesophageal reflux disease (GERD) is a highly prevalent gastrointestinal disorder. Proton pump inhibitors have profoundly revolutionized the treatment of GERD. However, several areas of unmet need persist despite marked improvements in the ther-apeutic management of GERD. These include the advanced grades of erosive esophagitis, nonerosive reflux disease, main-tenance treatment of erosive esophagitis, refractory GERD, postprandial heartburn, atypical and extraesophageal manifestations of GERD, Barrett's esophagus, chronic protein pump inhibitor treatment, and post-bariatric surgery GERD. Consequently, any fu-ture development of novel therapeutic modalities for GERD (medical, endoscopic, or surgical), would likely focus on the afore-mentioned areas of unmet need.

Keywords: Gastroesophageal Reflux; Heartburn; Proton Pump Inhibitors.

PubMed Disclaimer

References

    1. Peery AF, Dellon ES, Lund J, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology. 2012;143:1179–1187. e1–e3. doi: 10.1053/j.gastro.2012.08.002. - DOI - PMC - PubMed
    1. Hershcovici T, Fass R. Nonerosive reflux disease (NERD) - An Update. J Neurogastroenterol Motil. 2010;16:8–21. doi: 10.5056/jnm.2010.16.1.8. - DOI - PMC - PubMed
    1. Dekel R, Morse C, Fass R. The role of proton pump inhibitors in gastro-oesophageal reflux disease. Drugs. 2004;64:277–295. doi: 10.2165/00003495-200464030-00004. - DOI - PubMed
    1. Coron E, Hatlebakk JG, Galmiche JP. Medical therapy of gastroesophageal reflux disease. Curr Opin Gastroenterol. 2007;23:434–439. - PubMed
    1. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999;45:172–180. doi: 10.1136/gut.45.2.172. - DOI - PMC - PubMed

LinkOut - more resources